{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:56:33Z","timestamp":1789692993090,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer, Inc. (New York, NY, USA)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Limited real-world data from routine clinical care are available on the safety and effectiveness of treatment with taliglucerase alfa in patients with Gaucher disease (GD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Taliglucerase Alfa Surveillance (TALIAS), a multinational prospective Drug Registry of patients with GD, was established to evaluate the long-term safety (primary objective) and effectiveness (secondary objective) of taliglucerase alfa. We present an interim analysis of the data from the Drug Registry collected over the 5-year period from September 2013 to January 2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 106 patients with GD (15.1% children aged\u2009&lt;\u200918\u00a0years; 53.8% females) treated with taliglucerase alfa have been enrolled in the Drug Registry, as of January 7, 2019. The median duration of follow-up was 795\u00a0days with quartiles (Q1, Q3) of 567 and 994\u00a0days. Fifty-three patients (50.0%) were from Israel, 28 (26.4%) were from the United States, and 25 (23.6%) were from Albania. At the time of enrollment, most patients (87.7%) had received prior enzyme replacement therapy (ERT). Thirty-nine of the 106 patients had treatment-emergent adverse events (AEs). Twelve of the 106 patients experienced serious AEs; two patients experienced four treatment-related serious AEs. Four patients died, although none of the deaths was considered to be related to taliglucerase alfa treatment by the treating physicians. Nine patients discontinued from the study, including the four who died. At baseline, patients with prior ERT had a higher mean hemoglobin concentration and platelet counts than treatment-na\u00efve patients, likely reflecting the therapeutic effects of prior treatments. During follow-up, the hemoglobin concentration and platelet counts increased in the treatment-na\u00efve patients and remained relatively constant or increased slightly in patients with prior ERT. Spleen and liver volumes decreased in treatment-na\u00efve patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The interim data showed no new or emergent safety signals. The overall interim data are consistent with the clinical program experience and known safety and effectiveness profile of taliglucerase alfa.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02289-7","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:13:27Z","timestamp":1648808007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)"],"prefix":"10.1186","volume":"17","author":[{"given":"Lina","family":"Titievsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1103-296X","authenticated-orcid":false,"given":"Muhammad","family":"Younus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Quazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Wajnrajch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"2289_CR1","first-page":"1121","volume-title":"Williams hematology","author":"A Zimran","year":"2016","unstructured":"Zimran A, Elstein D, et al. Gaucher disease and related lysosomal storage diseases. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press O, Burns L, et al., editors. Williams hematology. 9th ed. McGraw-Hill Education; 2016. p. 1121\u201333.","edition":"9"},{"key":"2289_CR2","unstructured":"Rare disease database: Gaucher disease. National Organization for Rare Disorders; 2018. https:\/\/rarediseases.org\/rare-diseases\/gaucher-disease\/. Accessed 24 Feb 2021."},{"issue":"5","key":"2289_CR3","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.3928\/19382359-20180424-01","volume":"47","author":"M Li","year":"2018","unstructured":"Li M. Enzyme replacement therapy: a review and its role in treating lysosomal storage diseases. Pediatr Ann. 2018;47(5):e191\u20137.","journal-title":"Pediatr Ann"},{"issue":"21","key":"2289_CR4","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324(21):1464\u201370.","journal-title":"N Engl J Med"},{"key":"2289_CR5","unstructured":"Elelyso [package insert]. Pfizer Labs. November 2020."},{"key":"2289_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/PHMT.S93634","volume":"8","author":"P Gupta","year":"2017","unstructured":"Gupta P, Pastores GM. Spotlight on taliglucerase alfa in the treatment of pediatric patients with type I Gaucher disease. Pediatric Health Med Ther. 2017;8:73\u201381.","journal-title":"Pediatric Health Med Ther"},{"issue":"1","key":"2289_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-018-0776-8","volume":"13","author":"A Zimran","year":"2018","unstructured":"Zimran A, Wajnrajch M, Hernandez B, Pastores GM. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease. Orphanet J Rare Dis. 2018;13(1):36.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2289_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bcmd.2014.10.002","volume":"54","author":"A Zimran","year":"2015","unstructured":"Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. Blood Cells Mol Dis. 2015;54(1):9\u201316.","journal-title":"Blood Cells Mol Dis"},{"key":"2289_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bcmd.2016.10.005","volume":"68","author":"A Zimran","year":"2018","unstructured":"Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, et al. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase. Blood Cells Mol Dis. 2018;68:163\u201372.","journal-title":"Blood Cells Mol Dis"},{"issue":"22","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Terreros Munoz E, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767\u201373.","journal-title":"Blood"},{"issue":"4","key":"2289_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"GM Pastores","year":"2014","unstructured":"Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, et al. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53(4):253\u201360.","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/ajh.24369","volume":"91","author":"A Zimran","year":"2016","unstructured":"Zimran A, Duran G, Mehta A, Giraldo P, Rosenbaum H, Giona F, et al. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease. Am J Hematol. 2016;91(7):656\u201360.","journal-title":"Am J Hematol"},{"issue":"7","key":"2289_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ajh.24399","volume":"91","author":"GM Pastores","year":"2016","unstructured":"Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, et al. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Am J Hematol. 2016;91(7):661\u20135.","journal-title":"Am J Hematol"},{"key":"2289_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bcmd.2016.07.002","volume":"78","author":"A Zimran","year":"2019","unstructured":"Zimran A, Duran G, Giraldo P, Rosenbaum H, Giona F, Petakov M, et al. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naive patients with Gaucher disease. Blood Cells Mol Dis. 2019;78:14.","journal-title":"Blood Cells Mol Dis"},{"key":"2289_CR15","unstructured":"A multicenter, multicountry, postmarketing active surveillance taliglucerase alfa registry in patients with Gaucher disease [EUPAS4721]. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance; 2019 [updated September 13, 2019]. http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=9442. Accessed 24 Feb 2021."},{"key":"2289_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bcmd.2016.10.003","volume":"68","author":"H Lau","year":"2018","unstructured":"Lau H, Belmatoug N, Deegan P, Goker-Alpan O, Schwartz IVD, Shankar SP, et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: an analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 2018;68:226\u201331.","journal-title":"Blood Cells Mol Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:56:55Z","timestamp":1648821415000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02289-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Drug Registry protocol was approved by an institutional review board and\/or independent ethics committee at each participating site, in accordance with the local legislation and requirements. Before enrollment, a written, signed, and dated informed consent to participate in the Drug Registry was obtained from all patients or from legal guardians of pediatric patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LT is a former employee of Pfizer. TS, RW, MY, AP, KQ, MPW, BH, RM, LT, and L-JT are employees of and own stock in Pfizer. NW, CC, and PK served as consultants on the Scientific Steering Committee for this study and received grant\/research support from Pfizer. PSB\u2019s institution received grant\/research support from Pfizer for her participation on the Scientific Steering Committee for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}